Skip to main content

Table 2 Number (percentage) of RA patients with damage to any or to multiple large joints as well as with uni- or bilateral erosive (Larsen score ≥2) large joints after 11 years of follow-up, by initial randomization group

From: Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial

 

Original randomization group

 

FIN-RACo (n = 52)

SINGLE (n = 54)

Damage to any large joint

7 (13%)

 

15 (28%)

 

Damage to multiple (two to three) large joints

5 (10%)

 

10 (19%)

 

Radiographed joint

Unilateral damage

Bilateral damage

Unilateral damage

Bilateral damage

Shoulder

0

2 (4%)

4 (7%)

7 (13%)

Elbow

1 (2%)

0

1 (2%)

1 (2%)

Hip

3 (6%)

2 (4%)

4 (7%)

1 (2%)

Knee

3 (6%)

1 (2%)

2 (4%)

0

  1. FIN-RACo, study group treated for the first 2 years with a combination of three disease-modifying antirheumatic drugs, initially methotrexate, sulfasalazine, and hydroxychloroquine, with prednisolone; RA, rheumatoid arthritis; SINGLE, study group treated for the first 2 years with one disease-modifying antirheumatic drug, initially sulfasalazine, with or without prednisolone.